Methotrexate and liver health: a noninvasive check
Part of Digestive system clinical trials.
This study checks if methotrexate (a medicine used for certain immune and skin conditions) causes liver scarring. It uses a special ultrasound and blood tests to look for early signs of liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and taking methotrexate for a condition like lupus, rheumatoid arthritis, ankylosing spondylitis, psoriasis, or Behcet's disease.
- You do not have fatty liver disease (MAFLD).
- You do not have other chronic liver diseases like hepatitis B or C, autoimmune hepatitis, or alcoholic liver disease.
- You have no history of chronic heart failure or kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two different types of biologic treatments (anti-TNF and anti-IL-17) affect the liver in people with psoriatic arthritis. It compares their liver health to those on methotrexate alone.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study looks at how well methotrexate injections work in people with rheumatoid arthritis. It is designed for patients who are starting or changing to this type of methotrexate treatment.
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.